3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Phase 3
1
Phase 2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Primary Myelofibrosis
2
Myeloproliferative Disorders
2
Recurrence
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Interventions
Rituximab
28
Cyclophosphamide
14
ibrutinib
10
Vincristine
10
Prednisone
10
Doxorubicin
10
Bendamustine Hydrochloride
9
Radiotherapy
7
Peripheral Blood Stem Cell Transplantation
6
Filgrastim
6
zanubrutinib
5
acalabrutinib
4
Lenalidomide
4
Cyclosporine
4
orelabrutinib
3
Whole-Body Irradiation
3
R-CHOP protocol
3
Mycophenolic Acid
3
Melphalan
3
Interferon-alpha
3
Etoposide
3
Dexamethasone
3
Cytarabine
3
Cyclosporins
3
venetoclax
2
liposomal amphotericin B
2
fludarabine phosphate
2
fludarabine
2
VAP-cyclo protocol
2
Therapeutics
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Lymphoma, Mantle-Cell
×
parsaclisib
×
Clear all
NCT04849715
2022-04-29
CITADEL-310
Incyte Corporation
Phase 3
Withdrawn